All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 22 November 20262 min read

Novateor (NOVATEOR) Q2 FY27 Profit Up 550% on Lower Sales, But Core Business Falters

Novateor Research Laboratories posted a sharp profit jump in Q2 FY27, but a 38.5% revenue drop and an auditor's red flag on interest income raise questions about its core oral care business.

By Vinayak Gandhi, CFA · Created 18 November 2026

Novateor's Q2 FY27 net profit surged 550% year-on-year to ₹0.09 crore, yet revenue fell sharply by 38.5%. The profit is supported by other income, while its core SmileShine business faces a shrinking top line and operational challenges.

For Novateor Research Laboratories, the September quarter delivered a stark contradiction: a soaring bottom line atop a shrinking business. The maker of SmileShine teeth whitening products reported a net profit of ₹0.09 crore, a 550% jump from a loss a year ago. Yet this profit arrived alongside a 38.5% collapse in revenue to ₹1.52 crore, revealing a business where the core is weakening.

The numbers show a company moving in opposite directions. Sequentially, revenue improved 11.8% from the March quarter, but profit fell 25% as margins contracted.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY25 0.79, Q4 FY25 1.98, Q2 FY26 2.47, Q4 FY26 1.36, Q2 FY27 1.52. Q2 FY25 0.03, Q4 FY25 0.05, Q2 FY26 -0.02, Q4 FY26 0.12, Q2 FY27 0.09-4-2024Q2 '25Q4 '25Q2 '26Q4 '26Q2 '27
  • Revenue (₹ Cr), Q2 FY25: 0.79
  • Revenue (₹ Cr), Q4 FY25: 1.98
  • Revenue (₹ Cr), Q2 FY26: 2.47
  • Revenue (₹ Cr), Q4 FY26: 1.36
  • Revenue (₹ Cr), Q2 FY27: 1.52
  • Profit (₹ Cr), Q2 FY25: 0.03
  • Profit (₹ Cr), Q4 FY25: 0.05
  • Profit (₹ Cr), Q2 FY26: -0.02
  • Profit (₹ Cr), Q4 FY26: 0.12
  • Profit (₹ Cr), Q2 FY27: 0.09

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY25 0.79, Q4 FY25 1.98, Q2 FY26 2.47, Q4 FY26 1.36, Q2 FY27 1.5201234Q2 '25Q4 '25Q2 '26Q4 '26Q2 '27
  • Revenue (₹ Cr), Q2 FY25: 0.79
  • Revenue (₹ Cr), Q4 FY25: 1.98
  • Revenue (₹ Cr), Q2 FY26: 2.47
  • Revenue (₹ Cr), Q4 FY26: 1.36
  • Revenue (₹ Cr), Q2 FY27: 1.52

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY25 0.03, Q4 FY25 0.05, Q2 FY26 -0.02, Q4 FY26 0.12, Q2 FY27 0.09-2-1012Q2 '25Q4 '25Q2 '26Q4 '26Q2 '27
  • Profit (₹ Cr), Q2 FY25: 0.03
  • Profit (₹ Cr), Q4 FY25: 0.05
  • Profit (₹ Cr), Q2 FY26: -0.02
  • Profit (₹ Cr), Q4 FY26: 0.12
  • Profit (₹ Cr), Q2 FY27: 0.09

Net Profit Margin (%)

Net Profit Margin (%)Q2 FY25 3.8, Q4 FY25 2.5, Q2 FY26 -0.8, Q4 FY26 8.8, Q2 FY27 5.9-20%-10%0%10%20%Q2 '25Q4 '25Q2 '26Q4 '26Q2 '27
  • Net Profit Margin (%), Q2 FY25: 3.8
  • Net Profit Margin (%), Q4 FY25: 2.5
  • Net Profit Margin (%), Q2 FY26: -0.8
  • Net Profit Margin (%), Q4 FY26: 8.8
  • Net Profit Margin (%), Q2 FY27: 5.9
MetricCurrentQ2 FY27Same quarter LYQ2 FY26
Revenue (₹ Cr)
1.52YoY -38%
2.47
Profit (₹ Cr)
0.09YoY +550%
-0.02
Net Profit Margin (%)
5.9YoY +838%
-0.8

The Profit That Wasn't From Operations

The profit leap is largely not from selling products. According to mCapital.in, the company's reported profit for the half-year relies significantly on ₹1.66 crore of disputed interest income recognized despite legal uncertainty. Excluding this, the core oral care operations remain loss-making. The auditor's qualified opinion, cited by Newboard.in, flags this along with unverifiable inventory and missing provisions.

A Top Line Under Siege

The steep annual revenue decline points to fundamental challenges in scaling the branded SmileShine business. Management has cited low customer awareness and pricing pressure from regional brands as key threats. A new three-year supply deal with Pidilite Industries, announced in October, offers a potential anchor, but the current sales run-rate is concerning.

Analysts at mCapital.in estimate the annualized revenue is tracking about 30% below last year's level, with operating losses deepening. This suggests the company's foray into new products like herb-based toothpaste sachets has yet to offset the broader decline.

Live Chart

· NOVATEOR

(BSE)

ISIN: INE08JY01013

Key Points

  • Net profit surged due to a high base effect from a year-ago loss and significant other income, not core operational strength.
  • Revenue fell sharply by 38.5% YoY, indicating severe pressure on the flagship SmileShine product portfolio.
  • The statutory auditor issued a qualified opinion, highlighting disputed interest income and issues with inventory valuation.
  • A new exclusive supply agreement with Pidilite Industries provides a potential revenue stream but does not immediately reverse the top-line contraction.

Hexa Perspective

The quarter underscores a business at a crossroads. The reported profit is a fragile construct, heavily dependent on non-operational and contested income. For the stock's premium valuation—trading at over 160 times earnings—to hold, investors need to see a convincing turnaround in the core revenue trajectory.

The Pidilite contract and planned move to a semi-automated plant in Sanand are positive steps, but as Newboard.in notes, these plans lack concrete timelines. The path to sustainable profitability runs directly through rebuilding sales volume for SmileShine in a crowded, price-sensitive market.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Novateor Research Laboratories (NOVATEOR) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Novateor Research Laboratories' Q2 FY27 results?
For Q2 FY27 (quarter ended September 2026), Novateor reported revenue of ₹1.52 crore, a 38.5% decline year-on-year. Net profit was ₹0.09 crore, a significant improvement from a loss of ₹0.02 crore in the same quarter last year.
Why did Novateor's Q2 FY27 revenue decline 38.5% year-on-year?
Novateor's revenue fell sharply due to challenges in scaling its core SmileShine branded business. The company's management has cited low customer awareness and intense pricing pressure from regional competitors in the oral care market as key factors behind the sales drop.
What caused the 25% quarter-on-quarter drop in net profit for Novateor in Q2 FY27 despite higher revenue?
Novateor's net profit fell 25% sequentially to ₹0.09 crore in Q2 FY27 because expenses grew faster than revenue. Interest costs rose 50% quarter-on-quarter, and the net profit margin contracted by 290 basis points, squeezing profitability.
Why did Novateor's net profit margin contract 290 basis points quarter-on-quarter in Q2 FY27?
Novateor's net profit margin fell from 8.8% to 5.9% sequentially due to a faster rise in total expenses, which increased 10.8% compared to an 11.8% rise in revenue. A significant 50% jump in interest expense was a key contributor to this margin pressure.
What drove the 50% quarter-on-quarter increase in interest expense for Novateor in Q2 FY27?
Novateor's interest expense increased by 50% quarter-on-quarter to ₹0.06 crore in Q2 FY27. The specific cause for this spike is not detailed in the results, but it contributed directly to the contraction in the company's net profit margin for the quarter.
What guidance did Novateor Research Laboratories management provide for the coming quarters?
Management has stated plans to expand into cosmetics and healthcare and move to a semi-automated plant in Sanand. However, as noted by Newboard.in, these plans are repeated without firm dates, and the company reported no R&D expenditure in FY26, offering limited near-term guidance.
What is the status of Novateor Research Laboratories' working capital and cash flow?
Novateor has historically seen negative cash flow from operations, with FY26 reporting an outflow of ₹0.18 crore against a profit of ₹0.10 crore. Newboard.in notes that large advances to suppliers and slow customer collections tie up capital, keeping operational cash flow weak.
What is the current demand for Novateor's SmileShine teeth whitening products?
Demand appears challenged, with revenue falling sharply. Analysts at mCapital.in estimate the annualized revenue run-rate is about 30% below FY26 levels. The company faces a crowded, fragmented market where regional brands discount aggressively online.
Did Novateor secure any major new contracts in Q2 FY27?
Yes, in October 2026, Novateor announced an exclusive three-year supply agreement with Pidilite Industries Limited to manufacture Aligner Cleaning Foam and Tooth Brightening Strips. This contract was secured after the close of Q2 FY27.
What are Novateor's capacity expansion plans?
Novateor plans to move manufacturing to a semi-automated plant on its GIDC Sanand plot and expand into cosmetics and healthcare products. However, according to Newboard.in, these plans lack concrete timelines, and the company reported no R&D expenditure in FY26.
Did Novateor's Q2 FY27 results beat analyst estimates?
While specific analyst estimates are not published, the results show a mixed picture. The profit beat year-ago levels dramatically, but the steep revenue miss and deeper operational challenges highlighted by analysts at mCapital.in suggest the core business performance was weak.
Have any brokerages changed their rating for Novateor after Q2 FY27 results?
No specific brokerage rating changes were found following the Q2 FY27 results. The stock's high valuation at over 160 times earnings and the qualified audit opinion are likely key points of analysis for any firm covering the company.
How did Novateor's stock price react to the Q2 FY27 results announcement?
Novateor's stock closed at ₹27.51 on November 19, 2026, down 14.03% on the day, according to Newboard.in. The stock has fallen 29.5% over the past month, reflecting negative market sentiment around the company's results and outlook.
Are there any regulatory concerns impacting Novateor's SmileShine products?
The primary concerns are accounting-related. The statutory auditor issued a qualified opinion for FY26, citing non-compliance with standards on inventory valuation and revenue recognition for disputed interest income. There is no mention of product-specific regulatory action from bodies like the FDCA.
Novateor Research Laboratories Q2 profit drop?
Novateor's Q2 FY27 net profit was ₹0.09 crore, which is a 25% drop from the ₹0.12 crore profit reported in the previous quarter (Q4 FY26). This decline occurred despite an 11.8% sequential increase in revenue.